Effectiveness and safety of modified fully oral 9-month treatment regimens for rifampicin-resistant tuberculosis: a prospective cohort studyOleksandr Korotych, Askar Yedilbayev, Nino Lomtadze et al.|The Lancet Infectious Diseases|2024Cited by 23
Culture Conversion at 6 Months in Patients Receiving Delamanid-containing Regimens for the Treatment of Multidrug-resistant TuberculosisKwonjune J. Seung, Carole D. Mitnick, Palwasha Khan et al.|Clinical Infectious Diseases|2019Cited by 20